Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 110 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Hydroxymethylglutaryl-CoA Reductase Inhibitors [Clear All Filters]
Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study..
Diabetes Obes Metab. 14(2), 181-6.
(2012). The effects of vitamin E-coated membrane dialyzer compared to simvastatin in patients on chronic hemodialysis..
Ren Fail. 34(9), 1135-9.
(2012). Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance..
J Clin Lipidol. 6(1), 93.
(2012). Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis..
Angiology. 63(5), 358-66.
(2012). Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate..
Nat Rev Endocrinol. 8(3), 133-4.
(2012). Postoperative adhesion prevention using a statin-containing cellulose film in an experimental model..
Br J Surg. 99(3), 423-9.
(2012). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Statins, plaque regression, and arterial remodeling: systemic drug effect, local effect, or a combination thereof?.
Am J Cardiol. 110(2), 318.
(2012). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study..
Curr Med Res Opin. 27(8), 1659-68.
(2011). Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study..
Int J Clin Pract. 65(6), 679-83.
(2011). Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia..
Int Angiol. 30(3), 295; author reply 296.
(2011). Impact of statins on glucose metabolism--a matter of debate..
Am J Cardiol. 107(12), 1866.
(2011). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). Residual cardiac risk reduction beyond lipid lowering..
Hellenic J Cardiol. 52(3), 197-203.
(2011). Vitamin D deficiency, statin-related myopathy and other links with vascular risk..
Curr Med Res Opin. 27(9), 1691-2.
(2011). Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization..
J Vasc Surg. 51(1), 114-21.
(2010). Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?.
Curr Opin Cardiol. 25(4), 406-10.
(2010). Atorvastatin: safety and tolerability..
Expert Opin Drug Saf. 9(4), 667-74.
(2010). Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis..
Eur J Vasc Endovasc Surg. 39(3), 258-65.
(2010). Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence..
Angiology. 61(2), 137-44.
(2010). Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?.
Atherosclerosis. 211(1), 9-14.
(2010). Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia..
Arch Cardiovasc Dis. 103(1), 26-32.
(2010). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy..
Expert Opin Pharmacother. 11(5), 723-30.
(2010).